About the Team
Join a world-class team at the forefront of AI and biochemistry.
At Genesis Therapeutics, we’re a tight-knit team of proven deep learning researchers, software engineers, and drug discovery pioneers. Our shared mission is nothing short of revolutionary: to forge the next generation of AI foundation models that will unlock groundbreaking therapies for patients with severe diseases.
We don’t just apply machine learning to biology; we are conducting fundamental research at the intersection of machine learning, physics, and computational chemistry, pushing the boundaries of each field. The Genesis AI team is building an engine for this revolution. You will work side by side with the top multidisciplinary researchers to design and build generative and discriminative foundation models at scale from the entire spectrum of molecular data, having access to ample compute and large-scale simulations.
About the Role
This is an opportunity for a scientific innovator to advance the future of generative AI in drug discovery. As a key member of the Genesis AI team, you will shape and drive our research agenda for foundation models. You will lead critical research initiatives in areas like reinforcement learning, novel model architectures, and advanced pretraining and post-training methods. Your core mission is to create groundbreaking models and insights that are instrumental in discovering new medicines.
This role requires a deep curiosity and a collaborative spirit. You will be a strong team player, working in close partnership with our exceptional engineers and drug discovery experts to bring complex ideas to life. We also want you to be a voice in the scientific community. We will actively support and champion your efforts to publish some research breakthroughs in premier ML venues such as NeurIPS, ICML, and ICLR.
Positions are available at various levels of seniority: Senior, Staff, and Principal.
About Genesis Therapeutics
Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules. Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets.
The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI-focused platform collaborations with major pharmaceutical companies, including most recently Incyte Corporation (Feb 2025) and Gilead Sciences (Sept 2024). We raised a $200M series B in August 2023, and have raised over $300M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures.
Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.